Biofrontera Inc. (BFRI) IPO - S-1 Filing, Stock & Insider Activity
Biofrontera Inc. IPO - Status & S-1 Filing
- Ticker: BFRI
- Status: Registered - S-1 filed with the SEC
- S-1 filed: 2025-12-05
- Expected price range: not yet disclosed (set in a later S-1/A or pricing amendment)
- SEC CIK: 0001858685 · View the S-1 on SEC EDGAR →
Track every registration update on the InsiderAlpha IPO tracker.
Last SEC filing
Biofrontera Inc. (BFRI) has filed 2 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-29. 2 Form 8-K material event filings were reported by BFRI in the last 90 days. InsiderAlpha tracks every BFRI SEC filing - Form 4, Form 144, and 8-K - in real time, including Rule 10b5-1 plan detection.
About Biofrontera Inc. (BFRI)
Biofrontera Inc. trades under the ticker BFRI. InsiderAlpha tracks 17 primary SEC Form 4 filings from 8 reporting insiders for BFRI since 2025, sourced directly from SEC EDGAR.
| Sector | Health Care insider trading |
|---|---|
| SIC classification | Pharmaceutical Preparations (SIC 2834) |
| SEC CIK | 0001858685 |
90-Day SEC Filing Activity
| Form 4 filings (90d) | 2 |
|---|---|
| Form 8-K filings (90d) | 2 |
| Latest Form 4 filing | 2026-07-29 |
Recent BFRI Insider Transactions (Form 4)
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Hermann Luebbert | CEO & Chairman | M - Option exercise | 62.5K | - | - | SEC | |
| Eugene Frederick Leffler | Chief Financial Officer | M - Option exercise | 31.2K | - | - | SEC | |
| Hermann Luebbert | CEO & Chairman | M - Option exercise | 137.5K | - | - | SEC | |
| Eugene Frederick Leffler | Chief Financial Officer | M - Option exercise | 87.5K | - | - | SEC | |
| Eugene Frederick Leffler | Chief Financial Officer | M - Option exercise | 87.5K | - | - | SEC | |
| Hermann Luebbert | CEO Chairman | M - Option exercise | 137.5K | - | - | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Biofrontera Inc. (BFRI). Updated in real time as new filings are submitted to the SEC.
Most-Active BFRI Insiders - Last 90 Days
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Eugene Frederick Leffler | 2 | - |
| Hermann Luebbert | 2 | - |
Recent BFRI Form 8-K Material Events
- - Item 5.07 [SEC]
- - Item 2.02, 9.01 [SEC]
- - Item 2.02, 9.01 · Earnings · neutral [SEC]
Biofrontera Inc. announced its financial and operational results for Q4 and fiscal year 2025 on March 19, 2026. The filing provides standard results reporting without explicit beat/miss language or forward guidance changes. - - Item 7.01, 9.01 · Clinical · positive [SEC]
Biofrontera announced positive Phase 2b trial results for Ameluz® PDT in treating moderate to severe acne vulgaris on March 9, 2026. The company disclosed the results via press release filed as a Regulation FD disclosure, representing a meaningful clinical milestone for the derma - - Item 8.01, 9.01 · Legal · positive [SEC]
The U.S. Patent Trial and Appeal Board issued a Final Written Decision on February 23, 2026, finding all challenged claims of Sun Pharmaceutical's U.S. Patent No. 11,697,028 unpatentable. This is a significant victory for Biofrontera in its ongoing patent dispute with Sun, though
Recent Insider Filings
- - Hermann Luebbert (CEO & Chairman)
- - Eugene Frederick Leffler (Chief Financial Officer)
- - Kevin Daniel Weber (Director)
- - Hermann Luebbert (CEO & Chairman)
- - Eugene Frederick Leffler (Chief Financial Officer)
Form 4 Transaction Code Reference
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in BFRI insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
BFRI Insider Trading - FAQ
- What is the latest insider trade for BFRI?
- Biofrontera Inc. (BFRI) had 2 insider filings in the last 90 days, with the most recent on 2026-07-29. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
- How many insiders are buying BFRI stock?
- 0 insider purchases of BFRI were filed in the last 90 days.
- How many insiders are selling BFRI stock?
- 0 insider sales of BFRI were filed in the last 90 days.
- Where can I see BFRI SEC filings (Form 4, 10-K, 10-Q, 8-K)?
- This page tracks BFRI Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care Companies with Insider Activity
Other companies in the InsiderAlpha index with a significant SEC Form 4 insider-trading footprint:
- $BHC Bausch Health Companies Inc.
- $BHVN Biohaven Ltd.
- $BIOA BioAge Labs, Inc.
- $BIVI BIOVIE INC.
- $CADL Candel Therapeutics, Inc.
- $CAMP Camp4 Therapeutics Corp
- $CARL CARLSMED, INC.
- $CBIO CRESCENT BIOPHARMA, INC.
- $CBLL Ceribell, Inc.
- $CELU Celularity Inc
Related Companies - Recent Insider Activity
- UNITED THERAPEUTICS Corp (UTHR)
- Liquidia Corp (LQDA)
- BeOne Medicines Ltd. (ONC)
- PERRIGO Co plc (PRGO)
- Processa Pharmaceuticals, Inc. (PCSA)
- Nuvalent, Inc. (NUVL)
- CYTOKINETICS INC (CYTK)
- Elanco Animal Health Inc (ELAN)
- Avalo Therapeutics, Inc. (AVTX)
- NATURES SUNSHINE PRODUCTS INC (NATR)
Learn More
- What is SEC Form 4?
- How to read insider buying signals
- Rule 10b5-1 trading plans explained
- The cluster buying signal
Open the live BFRI dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.